Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Reuters

昨天

Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545744702"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545744702\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545744702?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545744702","market":"us","top_or_hot":-1,"title":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 04:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL6JFmrN:1","article_id":"2545744702","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545744702","pubTimestamp":1750710882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx. Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty . This funding comes after the first commercial sale of YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial inte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","UTHR":"美国联合医疗","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4532":"文艺复兴科技持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4112":"金融交易所和数据","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LQDA":"Liquidia Technologies Inc","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4588":"碎股"},"translate_title":"Liquidia Corporation在YUTREPIA成功推出后扩大了制造能力，并从HCRx获得了5000万美元的额外资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":0.9,"NDAQ":0.9,"LQDA":0.9},"content_text":"Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx\n    \n\n        Liquidia Corporation, a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary diseases, has announced a significant expansion following its receipt of $50 million from Healthcare Royalty (HCRx). This funding comes after the first commercial sale of YUTREPIA™, an inhalation powder for treating pulmonary arterial hypertension, and the dismissal of legal challenges from United Therapeutics Corporation. The investment will accelerate YUTREPIA's market launch, enhance Liquidia's clinical pipeline, and support the establishment of a newly leased manufacturing facility. With a strong financial position and strategic partnerships, Liquidia aims to meet increasing market demand and achieve profitability without seeking additional capital.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9483132-en) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}